Quantum BioPharma Ltd. announced that its licensee Unbuzzd Wellness Inc. appointed Richard Buzbuzian as CEO to lead the nationwide commercialization of its clinically validated hangover remedy, unbuzzd, targeting the $198 billion functional beverage market.
Key takeaways
Unbuzzd Wellness Inc., licensee of Quantum BioPharma's unbuzzd product, appointed Richard Buzbuzian as CEO to execute a nationwide commercialization strategy.
The commercialization plan includes initial market expansion into South Florida and Texas, with the goal of listing Unbuzzd Wellness on a stock exchange.
Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness as of December 31, 2025, and is entitled to royalty payments of 7% of sales up to $250 million, then 3% in perpetuity.
The unbuzzd product is backed by a peer-reviewed clinical study published in the World Journal of Pharmaceutical and Medical Research, validating its efficacy in accelerating alcohol metabolism and reducing hangover symptoms.
The functional beverage market is projected to reach $198 billion in 2026 with a 10.79% CAGR, and unbuzzd targets this market through multi-channel distribution including retail and e-commerce.
Quantum BioPharma retains 100% rights to develop similar products or alternative formulations for pharmaceutical and medical uses, separate from the consumer product licensed to Unbuzzd Wellness.